Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CYP1A1 | P04798 | 5/20 | 0.34 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.34 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | PRNP | P04156 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19786535 | 0.96 | ATM (0.41) | KDM4EATML3MBTL1CYP1A1CYP1B1 | |
| SCHEMBL19786544 | 0.94 | MEN1 (0.33) | KDM4EATML3MBTL1CYP1A1CYP1B1 | |
| SCHEMBL19786550 | 0.92 | PMM2 (0.36) | CYP1A1CYP1B1CYP1A2RAB9A | |
| SCHEMBL19786533 | 0.92 | CYP1B1 (0.34) | CYP1A1CYP1B1HPRT1CYP1A2TDP1 | |
| SCHEMBL19786645 | 0.90 | CYP1A2 (0.38) | CYP1A1CYP1B1CYP1A2TDP1RAB9A | |
| SCHEMBL19786641 | 0.86 | CYP1A1 (0.40) | CYP1A1CYP1B1CYP1A2 | |
| SCHEMBL19786644 | 0.85 | CYP1A1 (0.41) | KDM4EATML3MBTL1CYP1A1CYP1B1 | |
| SCHEMBL15126943 | 0.85 | KDM4E (0.41) | KDM4EATML3MBTL1CYP1A1CYP1B1 | |
| SCHEMBL19786553 | 0.84 | CYP3A4 (0.32) | CYP1A1CYP1B1 | |
| SCHEMBL15126939 | 0.83 | CYP1A1 (0.39) | KDM4EATML3MBTL1CYP1A1CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190300535-A1 | COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC DEVICE USING SAME, AND ELECTRONIC DEVICE THEREOF | DUK SAN NEOLUX CO., LTD. (KR) | 2019-10-03 | — | — | US | disclosed |
| WO-2018012781-A1 | COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC DEVICE USING SAME, AND ELECTRONIC DEVICE THEREOF | 덕산네오룩스 주식회사 | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300535-A1 | COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC DEVICE USING SAME, AND ELECTRONIC DEVICE THEREOF | ORC3, OR51E2, ORAI2 | KDM4E 442/4885ATM 3467/4885L3MBTL1 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.